Hims & Hers Partners with Novo Nordisk for FDA-Approved GLP-1s, Resolves Lawsuit, and Shifts Weight Loss Strategy
HIMS sits 99% above its 52-week low of $13.74 on elevated volume (3.9× avg).
Summary
Hims & Hers Health announced a strategic collaboration with Novo Nordisk to offer FDA-approved GLP-1 weight-loss medications, including Ozempic and Wegovy, while significantly scaling back its compounded GLP-1 offerings and resolving a lawsuit with Novo Nordisk.
Key Events · M&A and Partnerships · HIMS
-
Strategic Collaboration with Novo Nordisk
Hims & Hers has partnered with Novo Nordisk to offer FDA-approved GLP-1 medications, formalizing a deal previously reported in news.
-
Expanded Access to Branded GLP-1s
The platform will now provide Ozempic® and Wegovy® injections and pills, expanding access to a broad assortment of FDA-approved treatments later this month.
-
Strategic Shift in Weight Loss Offerings
The company will no longer advertise compounded GLP-1 offerings and will limit their availability to clinically necessary cases, aligning with a focus on FDA-approved drugs.
-
Lawsuit Dismissal by Novo Nordisk
Novo Nordisk has dismissed its lawsuit against Hims & Hers without prejudice, removing a significant legal and reputational overhang.
Analysis · HIMS · Industrial Applications And Services
This 8-K signals a pivotal strategic shift for Hims & Hers in the rapidly evolving GLP-1 weight loss market. The collaboration with Novo Nordisk, a leader in GLP-1s, secures access to highly demanded FDA-approved medications like Ozempic and Wegovy, which is crucial for long-term growth and credibility. The company's decision to de-emphasize compounded GLP-1s and cease their advertising, while potentially impacting some existing offerings, aligns with increasing regulatory scrutiny and consumer preference for branded, approved treatments. Critically, the dismissal of Novo Nordisk's lawsuit removes a significant legal and reputational risk, allowing Hims & Hers to focus on expanding its legitimate GLP-1 offerings. This move positions the company more strongly in the competitive telehealth landscape for weight management.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HIMS was trading at $27.39 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $13.74 to $70.43. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.